Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Ciclopirox Ethanolamine Is a Novel Modifier of Human Hematopoietic Stem Cell Ex Vivo Expansion

Mehrnaz Safaee Talkhoncheh, PhDcandidate, Fredrik Ek, PhD, Aurelie Baudet, PhD, Christine Karlsson, PhD, Roger Olsson, PhD, Jonas Larsson, MD PhD

Blood (2015) 126 (23): 36.

https://doi.org/10.1182/blood.V126.23.36.36

Published: 2015

Journal Articles

Clinical Proof of Concept Trial of Oral Ciclopirox Olamine in Patients with Relapsed/Refractory Hematologic Malignancy

Mark D. Minden, MD, PhD, FRCPC, Donna E. Hogge, MD, PhD, FRCPC, Scott Weir, PharmD, PhD, Jim Kasper, MS, Lavonne Patton, PhD, Yulia Jitkova, PhD, Marcela Gronda, MSc, Rose Hurren, BSc, Lian Rajewski, Kevin Schorno, MBA, Hong Chang, Joseph M. Brandwein, MD, Vikas Gupta, MD, FRCP, FRCPath, Andre C. Schuh, MD, FRCPC, Suzanne Trudel, MD, MSC, FRCPC, Karen W.L. Yee, MD, FRCP, Greg Reed, Aaron D Schimmer, MD, PhD

Blood (2012) 120 (21): 1372.

https://doi.org/10.1182/blood.V120.21.1372.1372

Published: 2012

Journal Articles

Eberhard Y, McDermott SP, Wang X, et al. Chelation of intracellular iron with the antifungal agent ciclopirox olamine induces cell death in leukemia and myeloma cells. Blood . 2009;114(14): 3064–3073 .

Blood (2010) 115 (19): 4006.

https://doi.org/10.1182/blood-2010-03-274993

Published: 2010

Journal Articles

Chelation of intracellular iron with the antifungal agent ciclopirox olamine induces cell death in leukemia and myeloma cells

Yanina Eberhard, Sean P. McDermott, Xiaoming Wang, Marcela Gronda, Amudha Venugopal, Tabitha E. Wood, Rose Hurren, Alessandro Datti, Robert A. Batey, Jeffrey Wrana, William E. Antholine, John E. Dick, Aaron D. Schimmer

Blood (2009) 114 (14): 3064–3073.

https://doi.org/10.1182/blood-2009-03-209965

Published: 2009

Includes: Supplemental data

Journal Articles

Screens, iron, and leukemia

Richard M. Stone, Daniel J. DeAngelo

Blood (2009) 114 (14): 2857–2858.

https://doi.org/10.1182/blood-2009-08-234161

Published: 2009

Journal Articles

The off-Patent Anti-Fungal Ciclopirox Olamine Displays Preclinical Activity in Leukemia and Myeloma.

Yanina Eberhard, Amudha Venugopal, Marcela Gronda, Rose Hurren, Alessandro Datti, Jeff Wrana, William E Antholine, Aaron D. Schimmer

Blood (2008) 112 (11): 944.

https://doi.org/10.1182/blood.V112.11.944.944

Published: 2008

Journal Articles

Molecular Signature for Parthenolide-Induced Apoptosis in AML CD34+ Cells Reveals Targets for Improving Induction of Leukemia-Specific Cell Death.

Duane C. Hassane, PhD, Monica L. Guzman, PhD, Xiaojie Li, MS, Cheryl Corbett, BS, Craig T. Jordan, PhD

Blood (2006) 108 (11): 2592.

https://doi.org/10.1182/blood.V108.11.2592.2592

Published: 2006

Journal Articles

Combination of Imatinib and Hypusination Inhibitors Represents a Novel Therapeutic Strategy in Bcr-Abl Positive Leukemias.

Stefan Balabanov, MD, PhD, Artur Gontarewicz, MD, Patrick Ziegler, PhD, Ulrike Hartmann, PhD, Mhairi Copland, MD, Ute Brassat, Ilona Hauber, PhD, Lothar Kanz, MD, Carsten Bokemeyer, MD, Alfred Nordheim, PhD, Joachim Hauber, PhD, Tessa L. Holyoake, MD, Tim H. Brummendorf, MD

Blood (2006) 108 (11): 1379.

https://doi.org/10.1182/blood.V108.11.1379.1379

Published: 2006

Journal Articles

Inhibition of Hypusination of Eukaryotic Initiation Factor 5a (eIF-5A) as a Novel a Synergistic Treatment Strategy in Imatinib-Treated BCR-ABL Positive Leukemias Identified by a Global Proteomics Approach.

Stefan Balabanov, MD, PhD, Patrick Ziegler, PhD, Ulricke Hartmann, Winfried Kammer, PhD, Mhairi Copland, MD, Martin Priemer, Thomas Wilhelm, Carsten Bokemeyer, MD, Lothar Kanz, MD, Tessa Holyoake, MD, Alfred Nordheim, PhD, Tim Bruemmendorf, MD

Blood (2005) 106 (11): 1997.

https://doi.org/10.1182/blood.V106.11.1997.1997

Published: 2005

Journal Articles

Identification of Hypusination Inhibitors as a Novel Therapuetical Option in BCR-ABL Positive Leukemias Using a Proteomics Approach.

Stefan Balabanov, MD PhD, Ulrike Hartmann, Winfried Kammer, PhD, Patrick Ziegler, PhD, Martin Priemer, Gerold Schwarz, Lothar Kanz, MD, Alfred Nordheim, PhD, Tim H. Brummendorf, MD

Blood (2004) 104 (11): 2957.

https://doi.org/10.1182/blood.V104.11.2957.2957

Published: 2004

NARROW

Ciclopirox Ethanolamine Is a Novel Modifier of Human Hematopoietic Stem Cell Ex Vivo Expansion

Clinical Proof of Concept Trial of Oral Ciclopirox Olamine in Patients with Relapsed/Refractory Hematologic Malignancy

Eberhard Y, McDermott SP, Wang X, et al. Chelation of intracellular iron with the antifungal agent ciclopirox olamine induces cell death in leukemia and myeloma cells. Blood . 2009;114(14): 3064–3073 .

Chelation of intracellular iron with the antifungal agent ciclopirox olamine induces cell death in leukemia and myeloma cells

Screens, iron, and leukemia

The off-Patent Anti-Fungal Ciclopirox Olamine Displays Preclinical Activity in Leukemia and Myeloma.

Molecular Signature for Parthenolide-Induced Apoptosis in AML CD34+ Cells Reveals Targets for Improving Induction of Leukemia-Specific Cell Death.

Combination of Imatinib and Hypusination Inhibitors Represents a Novel Therapeutic Strategy in Bcr-Abl Positive Leukemias.

Inhibition of Hypusination of Eukaryotic Initiation Factor 5a (eIF-5A) as a Novel a Synergistic Treatment Strategy in Imatinib-Treated BCR-ABL Positive Leukemias Identified by a Global Proteomics Approach.

Identification of Hypusination Inhibitors as a Novel Therapuetical Option in BCR-ABL Positive Leukemias Using a Proteomics Approach.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only